Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis - Wikidata - awgldk - TriplyDB

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis

http://www.wikidata.org/entity/Q24625697

about

Nonalcoholic fatty liver disease: an emerging threat to obese and diabetic individuals Adjunctive antioxidants for bipolar disorder Non-alcoholic fatty liver disease: what the clinician needs to know.Nonalcoholic fatty liver disease: a comprehensive review of a growing epidemic Micronutrient Antioxidants and Nonalcoholic Fatty Liver Disease A Guide to Non-Alcoholic Fatty Liver Disease in Childhood and Adolescence Novel Action of Carotenoids on Non-Alcoholic Fatty Liver Disease: Macrophage Polarization and Liver Homeostasis The Immune Landscape in Nonalcoholic Steatohepatitis.Insulin resistance in development and progression of nonalcoholic fatty liver disease Utilization of animal models to investigate non-alcoholic steatohepatitis-associated hepatocellular carcinoma Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions A Comprehensive Updated Review of Pharmaceutical and Nonpharmaceutical Treatment for NAFLD Current Management of NAFLD The Role of Vitamins in the Pathogenesis of Non-alcoholic Fatty Liver Disease The Role of NADPH Oxidases (NOXs) in Liver Fibrosis and the Activation of Myofibroblasts Pharmacological Intervention in Hepatic Stellate Cell Activation and Hepatic Fibrosis Management of non-alcoholic fatty liver disease in 2015 Nutrition and Physical Activity in Nonalcoholic Fatty Liver Disease Preoperative selection of patients with colorectal cancer liver metastasis for hepatic resection The Role of Organelle Stresses in Diabetes Mellitus and Obesity: Implication for Treatment Nutritional Modulation of Non-Alcoholic Fatty Liver Disease and Insulin Resistance The Role of Oxidative Stress and Antioxidants in Liver Diseases Liver fibrosis in non-alcoholic fatty liver disease - diagnostic challenge with prognostic significance.Endocrine causes of nonalcoholic fatty liver disease Evidence for beneficial effects of vitamin E Oily fish, coffee and walnuts: Dietary treatment for nonalcoholic fatty liver disease Nonalcoholic steatohepatitis: emerging targeted therapies to optimize treatment options Non-Alcoholic Steatohepatitis: Limited Available Treatment Options but Promising Drugs in Development and Recent Progress Towards a Regulatory Approval Pathway The therapy of insulin resistance in other diseases besides type 2 diabetes Extracellular matrix and liver disease Pathophysiology guided treatment of nonalcoholic steatohepatitis Incretin based therapies: a novel treatment approach for non-alcoholic fatty liver disease Review of nonalcoholic fatty liver disease in women with polycystic ovary syndrome Non-alcoholic fatty liver disease: what has changed in the treatment since the beginning?Dietary habits and behaviors associated with nonalcoholic fatty liver disease Non-alcoholic fatty liver disease and diabetes: from physiopathological interplay to diagnosis and treatment Treatment of nonalcoholic steatohepatitis in adults: present and future Prevention of hepatocellular carcinoma: Focusing on antioxidant therapy Clinical features of pediatric nonalcoholic fatty liver disease: a need for increased awareness and a consensus for screening.Nonalcoholic fatty liver disease: update on pathogenesis, diagnosis, treatment and the role of S-adenosylmethionine

P2860

Q22299426-41A5B763-6682-4965-8E29-DDBF2EB2753C Q24198987-B8F04F46-7B6E-4457-B228-6897921516F7 Q24563068-CC08C681-F0F2-4989-8992-390694D0CF11 Q24563381-70304E37-7734-49F0-83A0-253A1E86EB5F Q26738646-946E2EEA-DDB2-49F9-AD19-3255D2D6693C Q26744488-CED762C7-2EF0-4E38-B1D5-A4EE160EB2B1 Q26746997-52D02D52-F118-4CAA-BF40-C575AAE0B8CF Q26747323-3D9B2BDF-EC47-43B1-B0BD-C0F52519A001 Q26748687-30E4652A-EE51-4A2E-8E82-704F03A2C7C1 Q26748807-BFE97E5D-E52E-417C-81D8-D07A8BE24216 Q26751258-D941D0A7-2645-4ECC-BF8D-29A1C3F09DF0 Q26752487-23FB46BD-B91A-40CA-B035-4026D42CDF60 Q26752729-BEAB8E43-DA7C-4191-BF67-90E7C5C38C27 Q26752762-3B670391-A653-4A37-9865-BDB2B7CAF89D Q26766479-4836BE2E-E0D1-485B-BF60-70502D540B36 Q26768588-D23EB41A-F3A9-4FFB-B529-9D5D2AE193FD Q26771148-770C00A3-D7E1-48BD-8449-598346ADEFAE Q26771752-14507C3C-A523-4706-93C8-46180BC6D42E Q26774687-3EAA421D-772F-447A-B8AB-D3021B4F4B20 Q26776377-7F2D14BA-DCCD-4682-BC90-5B3A9F87120F Q26778135-9D359396-DAEC-402F-8E03-7CA09BEB389B Q26779146-03CAC70D-AA71-429B-9307-48A216159329 Q26780252-4536B435-488D-4734-8293-A92D6271033C Q26780254-F9D4FCBA-F8EC-46C4-A36D-4817D7F7CACF Q26782132-1A591C08-FF85-4F2F-978B-D07E14139AD1 Q26784396-C52FC22C-BBBC-4FD9-96BD-812CADA19886 Q26796448-133A2597-F33D-4313-8226-E7F7227654A4 Q26800894-814B088D-18ED-4A1D-B555-EC269EA42D52 Q26822399-0796FD18-0D3A-4E2E-94D5-CEA08034FFE1 Q26823060-B388858B-0FF0-445D-BC27-F8396AE23285 Q26827117-F0783332-AE12-43CA-83DE-C9D39A7D7AC7 Q26827183-BC12A9EE-7140-4464-A897-663378F10219 Q26828765-662C7194-AEF4-4379-ADAF-EEC9DA894CD5 Q26829503-7A782907-2F7B-4FF7-B222-C5972749643A Q26830594-795A931A-3670-440C-9CF5-4E510ADDDAF0 Q26852019-E2C92DDD-28E0-4A3A-A5EB-D6F2E5D1C218 Q26852403-1F4BC4CB-001A-4920-9F02-E3451DEC5C65 Q26853520-B186BE5E-4491-46FF-8641-9DCF6AC8E621 Q26859406-8464EA84-852F-4A7B-89AB-EB67C5851DA0 Q26992163-53D99375-2D9C-45B7-AED4-332CFCE42D48

P2860

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis

http://www.wikidata.org/entity/Q24625697

description

2010 nî lūn-bûn

@nan

2010 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis

@ast

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis

@en

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis

@nl

type

label

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis

@ast

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis

@en

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis

@nl

prefLabel

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis

@ast

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis

@en

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis

@nl

P1433

Q24625697-6A517440-EB99-48B5-A34F-B6E3F592CC17

P1476

Q24625697-8CB11E03-36B5-48CD-8DA9-06133CC3A91C

P2093

Q24625697-25C6CAD2-AE65-4947-94EF-A711A08A78DA

Q24625697-30CB6CE5-9F8F-426B-9937-103D6E8787F4

Q24625697-4221EC1C-A9D1-44D0-9E36-0A2E890869D4

Q24625697-493C492A-5AC1-4E22-AD50-F87BFC2CCCE0

Q24625697-547A9CE5-B8E6-44DB-A3E1-40368535341B

Q24625697-906C733D-7C1E-46E3-BABC-B6B647FB9E07

Q24625697-B6858272-0107-485B-B93F-65E04B4BAFD3

Q24625697-B93D7011-9374-42B4-96FA-7EC9270C0E1B

Q24625697-B9834E77-7629-4E8A-9563-953AA34B0C53

Q24625697-D53801E5-9688-43AF-BDEC-0B721FE6B45B

P2860

Q24625697-06DE3689-3FBA-44AC-B8FA-F881CBD6B5F8

Q24625697-0D86123D-41EA-45CA-8394-A7575081D746

Q24625697-13ED0F53-85A9-4ADC-BBC7-C38D5A3928B9

Q24625697-1D5C0A6E-851F-4A56-A846-25EF56EC0978

Q24625697-22713C95-0D7B-4DD4-B482-4EDE15098896

Q24625697-3B0EA020-D858-4468-B47E-C43F9F81F534

Q24625697-41CAD005-DE0A-4DBD-B91E-6DBEC0EEAC41

Q24625697-47BEB76B-0140-49E7-9FBA-64B7F65BF194

Q24625697-495E2473-316F-4524-933A-198F8ED30FCA

Q24625697-4E882BB4-CF40-4712-9272-508EDAD6099E

P304

Q24625697-938AF1C0-259F-40C0-8D17-138D91A4EFF2

P31

Q24625697-26E74EE1-8303-4241-9237-DD0CA4094D95

P3181

Q24625697-E5472F12-4966-4C56-A00A-6C35D9AB7289

P356

Q24625697-3944C20A-ABA5-40BF-8E9A-0C7A98FB20A2

P407

Q24625697-04563C10-BDD9-4172-84BD-520C1FBA7D05

P433

Q24625697-EA0790BF-5574-4BCF-AE77-5F5674FC8505

P478

Q24625697-7A623013-B22E-4047-A27B-9F82807062DF

P50

Q24625697-77F4DBA0-10AE-4715-ACEC-31F2F900EF89

P577

Q24625697-7140188D-39E0-4CB0-B343-F722A1EDDEB0

P5875

Q24625697-F428D3D0-986C-4562-83DF-BF52036DB64B

P698

Q24625697-C972400B-F03F-4A39-97F4-55D1081F0F87

P921

Q24625697-DB7D8CC9-580D-4AC0-BF8D-C645AF5608D0

Q24625697-E17AFE6F-183C-4F07-8B0E-20D04884D6DF

Q24625697-db6cb01b-7776-45b9-9100-4d93f6e77992

P932

Q24625697-17276DC9-A765-41AC-B2DE-A3BDC1C80390

P3181

P356

P1433

The New England Journal of Medicine

P1476

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis

@en

P2093

Anna Mae Diehl

http://www.w3.org/2001/XMLSchema#string

Arthur McCullough

http://www.w3.org/2001/XMLSchema#string

Arun J Sanyal

http://www.w3.org/2001/XMLSchema#string

Aynur Unalp

http://www.w3.org/2001/XMLSchema#string

Brent A Neuschwander-Tetri

http://www.w3.org/2001/XMLSchema#string

Elizabeth M Brunt

http://www.w3.org/2001/XMLSchema#string

James Tonascia

http://www.w3.org/2001/XMLSchema#string

Jay H Hoofnagle

http://www.w3.org/2001/XMLSchema#string

Jeanne Clark

http://www.w3.org/2001/XMLSchema#string

Joel E Lavine

http://www.w3.org/2001/XMLSchema#string

P2860

Nonalcoholic fatty liver disease: a feature of the metabolic syndrome

Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease

Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality

Nonalcoholic Fatty Liver Disease: A Feature of the Metabolic Syndrome

Design and validation of a histological scoring system for nonalcoholic fatty liver disease

Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity

Long-term follow-up of patients with NAFLD and elevated liver enzymes

A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis.

Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD): a histologic marker of advanced NAFLD-Clinicopathologic correlations from the nonalcoholic steatohepatitis clinical research network

Pioglitazone versus vitamin E versus placebo for the treatment of non-diabetic patients with non-alcoholic steatohepatitis: PIVENS trial design.

P304

1675-85

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

688209

http://www.w3.org/2001/XMLSchema#string

P356

10.1056/NEJMOA0907929

http://www.w3.org/2001/XMLSchema#string

P407

P433

18

http://www.w3.org/2001/XMLSchema#string

P478

362

http://www.w3.org/2001/XMLSchema#string

P50

David E. Kleiner

P577

2010-05-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

43351797

http://www.w3.org/2001/XMLSchema#string

P698

20427778

http://www.w3.org/2001/XMLSchema#string

P921

Steatohepatitis

P932

2928471

http://www.w3.org/2001/XMLSchema#string